Cargando…

Omalizumab Has a Place in Therapy for Asthma Disease Management

Detalles Bibliográficos
Autor principal:	Pesko, Lawrence J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2009
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438359/ https://www.ncbi.nlm.nih.gov/pubmed/19326960 http://dx.doi.org/10.18553/jmcp.2009.15.3.284

Ejemplares similares

Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)

Omalizumab: Clinical Use for the Management of Asthma
por: Thomson, Neil C., et al.
Publicado: (2012)

A review of omalizumab for the management of severe asthma
por: Lin, Ching-Hsiung, et al.
Publicado: (2016)

Update on optimal use of omalizumab in management of asthma
por: Pelaia, Girolamo, et al.
Publicado: (2011)

Identifying Patients for Self-Administration of Omalizumab
por: Murphy, Kevin R., et al.
Publicado: (2022)

Omalizumab and Other New Drug Therapies Occupy a Small Space in Asthma Disease Management
por: Curtiss, Frederic R.
Publicado: (2009)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Severe asthma and the omalizumab option
por: Miller, Christopher WT, et al.
Publicado: (2008)

Omalizumab treatment in brittle asthma
por: Skiepko, Roman, et al.
Publicado: (2014)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
por: Scioscia, Giulia, et al.
Publicado: (2020)

T cell activity in successful treatment of chronic urticaria with omalizumab
por: Sánchez-Machín, Inmaculada, et al.
Publicado: (2011)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018)

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report
por: Jeimy, Samira, et al.
Publicado: (2019)

279 Near-Fatal Asthma Treated with Omalizumab
por: Contreras Contreras, Elvia Angelica, et al.
Publicado: (2012)

Omalizumab therapy in a patient with severe asthma and co-existing chronic obstructive pulmonary disease
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2018)

Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbation
por: Skiepko, Roman, et al.
Publicado: (2014)

Is Omalizumab a Problem-Solving Remedy in Severe Asthma?
por: Kim, Doh Hyung, et al.
Publicado: (2018)

Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
por: Giovannini, Mattia, et al.
Publicado: (2019)

In search of clinically relevant parameters to monitor successful omalizumab therapy in allergic asthma
por: Probst, M., et al.
Publicado: (2019)

Omalizumab: clinical use for the treatment of an adolescent with difficult asthma
por: De Castro, Giovanna, et al.
Publicado: (2013)

Benefits of omalizumab on anxiety and depression in patients with severe asthma
por: Uzer, Fatih, et al.
Publicado: (2018)

Appropriate selection for omalizumab treatment in patients with severe asthma?
por: Nygaard, Leo, et al.
Publicado: (2017)

Omalizumab in patients with severe asthma and persistent sputum eosinophilia
por: Mukherjee, Manali, et al.
Publicado: (2019)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Age of asthma onset does not impact the response to omalizumab
por: Rogers, Linda, et al.
Publicado: (2023)

Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma
por: Zafari, Zafar, et al.
Publicado: (2016)

Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
por: Pennington, Luke F., et al.
Publicado: (2016)

Omalizumab as a new therapeutic approach for children with severe asthma
por: Jerzyńska, Joanna, et al.
Publicado: (2014)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

COVID‐19 in a patient with severe asthma treated with Omalizumab
por: Lommatzsch, Marek, et al.
Publicado: (2020)

The dynamics of the manifestations of atopic dermatitis in severe persistent uncontrolled asthma children with omalizumab therapy
por: Vishneva, Elena, et al.
Publicado: (2015)

When single-inhaler triple therapy is a preferred option in asthma management?
por: Al-Moamary, Mohamed S., et al.
Publicado: (2022)

A case report of ABPA, cystic fibrosis and asthma treated with omalizumab
por: Mazza, JA, et al.
Publicado: (2015)

282 Successful Treatment of Severe Nonallergic Asthma by Omalizumab. An Observation
por: Bergmann, Karl-Christian, et al.
Publicado: (2012)

270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Omalizumab treatment of moderate to severe asthma in the adolescent and pediatric population
por: O’Quinn, John, et al.
Publicado: (2014)

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
por: Zafari, Zafar, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6ibl0jkuq4da3s2he54dojl3il